Ad Scientiam

Ad Scientiam

Better data for better care

Founded 2013 France

France 59 employees Venture round Total: $2.00M Health Care, IT +1

Ad Scientiam, founded in 2013 and headquartered in France, is dedicated to revolutionizing healthcare with its slogan "Better data for better care." The company's primary focus is to continuously measure and monitor the progression of serious diseases through the development and clinical validation of digital biomarkers. This approach empowers patients to actively participate in their own care and enables healthcare professionals to deliver more personalized and efficient treatment. Ad Scientiam has gained the trust of prominent institutions such as the Brain Institute (ICM) and leading pharmaceutical companies including Biogen, Janssen, Roche, Pfizer, Vertex, and Novartis. In 2018, the company launched MSCopilot®, the first and only CE-marked software medical device for self-assessment of multiple sclerosis patients. Currently, Ad Scientiam is in the process of validating new devices for use in neuroscience, rare diseases, and mental disorders. The company secured a significant €2.00M in its last Venture Round investment on 18 July 2017. With its innovative approach and strong industry collaborations, Ad Scientiam is playing a crucial role in the development of future treatments and in reducing the societal and economic impact of diseases, positioning itself as a promising player in the intersection of Health Care and Information Technology.

Funding Stage	Amount	Investors	Lead Investors	Date
Venture Round	€2.00M	-		18 Jul 2017
Non Equity Assistance	Undisclosed	-		01 Sep 2015

Funding Stage

Amount

Investors

Lead Investors

Date

Venture Round

€2.00M

18 Jul 2017

Non Equity Assistance

Undisclosed

01 Sep 2015

FAQ About Ad Scientiam

Better data for better care

Ad Scientiam was founded in 2013.

Ad Scientiam is headquartered in France.

Ad Scientiam operates in Health Care, IT and Information Technology. Its work centres on digital biomarkers, medical device, real world data and mHealth. Its customers include Healthcare providers, medical researchers and pharmaceutical companies.

Ad Scientiam has approximately 59 employees.

Ad Scientiam has completed 2 funding rounds, raising a total of $2.00M. The latest funding stage is Venture round.

Ad Scientiam offers: Development and implementation of digital biomarkers for continuous and real-world disease monitoring, leveraging smartphone technology and proprietary algorithms..

Top alternatives and competitors to Ad Scientiam include Breakthrough, uMotif, PatientsLikeMe, eSteps Health 🐜, Medical Intelligence One. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.

Ad Scientiam and Breakthrough are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

General Information

Discover More

About Ad Scientiam

Services & Products

Target Customers

Funding Rounds & Investors (2)

Ad Scientiam Alternatives & Competitors

FAQ About Ad Scientiam